Compare MPB & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MPB | IMMX |
|---|---|---|
| Founded | 1868 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 827.5M | 716.2M |
| IPO Year | 1996 | 2021 |
| Metric | MPB | IMMX |
|---|---|---|
| Price | $35.27 | $9.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $37.00 | $19.20 |
| AVG Volume (30 Days) | 196.5K | ★ 2.3M |
| Earning Date | 04-21-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.66% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $30.95 | N/A |
| Revenue Next Year | $9.45 | N/A |
| P/E Ratio | $97.92 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.50 | $1.94 |
| 52 Week High | $37.18 | $12.14 |
| Indicator | MPB | IMMX |
|---|---|---|
| Relative Strength Index (RSI) | 56.81 | 47.11 |
| Support Level | $30.82 | $7.99 |
| Resistance Level | $35.98 | $10.61 |
| Average True Range (ATR) | 0.81 | 0.94 |
| MACD | 0.01 | -0.20 |
| Stochastic Oscillator | 43.22 | 26.80 |
Mid Penn Bancorp Inc is a financial holding company, providing various banking and financial products and services through its subsidiaries. These products and services mainly include consumer banking products, including secure checking and savings accounts, mobile banking, agricultural loans, construction financing, mortgages, home equity loans and lines of credit, credit cards, and more. Additionally, the Group offers trust services, insurance products, wealth management, and private banking services. The Group caters to individuals, partnerships, non-profit organizations, and corporations through its retail banking offices located throughout Pennsylvania, with a minor portion in New Jersey.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.